Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.65% | -3.56% | +33.53% | +60.50% | 63.48B | |
| +1.76% | +1.27% | +11.82% | +81.21% | 54.55B | |
| -0.94% | +0.99% | +10.45% | +100.19% | 53.59B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 44.75B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 41.62B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 39.91B | |
| +0.64% | -3.85% | +11.71% | +45.57% | 32.47B | |
| +29.06% | +47.63% | +107.12% | +92.73% | 26.7B | |
| +3.72% | -6.23% | +26.01% | -2.99% | 23.36B | |
| Average | +4.10% | -0.42% | +52.31% | +162.82% | 42.27B | |
| Weighted average by Cap. | +3.22% | -0.29% | +47.66% | +161.47% |
Employees
51
